Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., today announced the presentation of two sets of preclinical data demonstrating that ghrelin antagonism may be a potential method for future treatment of a range of metabolic disorders. These data demonstrated a variety of beneficial metabolic effects, notably decreasing body weight, improvements in blood glucose and insulin levels, and reductions in fatty liver. The data were presented in poster sessions on Sunday, June 24th, during the American Diabetes Association’s 67th Annual Scientific Sessions meeting, being held in Chicago, IL. Elixir is focused on the development of drugs to treat and prevent metabolic disease, as well as prevent age-related diseases, based on targets identified in the pathways regulating aging.